TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19305238

Group type: EXPERIMENTAL
Intervention: Interval Training (IT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Continuous Training (CT)
Number of subjects: 41
Study: 16948674

Group type: EXPERIMENTAL
Intervention: Oral Health Impact Profile (OHIP14)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Oral Impacts on Daily Performance (OIDP)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: OHRQoL (as measured by OIDP)
Number of subjects: 85
Study: 15374557

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 24

Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 24
Study: 11739158

Group type: EXPERIMENTAL
Intervention: Busulfan plus cyclophosphamide (Bu-CY)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Cyclophosphamide plus total-body irradiation (CY-TBI)
Number of subjects: 488

Group type: COMPARATOR
Intervention: CY-TBI
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Bu-CY
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 488
Study: 9236968

Group type: EXPERIMENTAL
Intervention: Multicomponent phone call intervention (reminder, counseling, scheduling)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Birthday card reminder only (standard method)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Personalized letter from the medical director and materials promoting mammography
Number of subjects: 395
Study: 8215552

Group type: EXPERIMENTAL
Intervention: 2 ml of 7.5% sucrose
Number of subjects: 52

Group type: COMPARATOR
Intervention: 2 ml of sterile water (control)
Number of subjects: 52
Study: 3139429

Group type: EXPERIMENTAL
Intervention: Terfenadine (full and half dosage)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranitidine (standard and four-fold higher dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of terfenadine and ranitidine (standard and modified dosage)
Number of subjects: 0
Study: 31324446

Group type: EXPERIMENTAL
Intervention: Benson's muscle relaxation for 10 to 20 minutes
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 64
Study: 29077725

Group type: EXPERIMENTAL
Intervention: Ondansetron (0.15mg/kg)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 25590215

Group type: EXPERIMENTAL
Intervention: Total thyroidectomy + prophylactic central compartment lymph node dissection (TTx + pCCND)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Total thyroidectomy (TTx)
Number of subjects: 181
Study: 23948102

Group type: EXPERIMENTAL
Intervention: BMMSCs transplantation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no cell transplantation)
Number of subjects: 40
Study: 21565344

Group type: EXPERIMENTAL
Intervention: Headphone music
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Broadcast music
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 167
Study: 18708179

Group type: EXPERIMENTAL
Intervention: Amblyopic eye
Number of subjects: 79

Group type: COMPARATOR
Intervention: Fellow eye
Number of subjects: 79
Study: 16557616

Group type: EXPERIMENTAL
Intervention: Indigenous (Black) defendant
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: White defendant
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Female jurors
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Same-race trials
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Mixed-race trials
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Female jurors in mixed-race trials
Number of subjects: 96
Study: 14511223

Group type: EXPERIMENTAL
Intervention: Eucalyptol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dimethylformamide (DMF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No solvent
Number of subjects: 30
Study: 10901337

Group type: COMPARATOR
Intervention: Alprazolam for PMS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzodiazepine therapy for GAD (diazepam and lorazepam)
Number of subjects: 0
Study: 8627060

Group type: EXPERIMENTAL
Intervention: High-dose zidovudine (180 mg/m2/dose)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Low-dose zidovudine (90 mg/m2/dose)
Number of subjects: 426
Study: 1418392

Group type: EXPERIMENTAL
Intervention: Terfenadine (120 mg/day) and nimesulide (200 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Terfenadine (120 mg/day) and placebo
Number of subjects: 30
Study: 6504947

Group type: EXPERIMENTAL
Intervention: Once-daily dosage of hydrochlorothiazide (25 mg), amiloride (2.5 mg), and timolol (10 mg)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Twice-daily dosage of hydrochlorothiazide (25 mg), amiloride (2.5 mg), and timolol (10 mg)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Both once-daily and twice-daily regimens
Number of subjects: 604
Study: 31798891

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) treatment for 12 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham-CPAP placebo for 12 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both groups received diabetes education and counseling
Number of subjects: 10
Study: 29432286

Group type: EXPERIMENTAL
Intervention: Extended-release carbidopa-levodopa (ER CD-LD)
Number of subjects: 484
Study: 27046330

Group type: EXPERIMENTAL
Intervention: Ciclosporin and Prednisolone (CnP)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Prednisolone only (P)
Number of subjects: 73
Study: 25257210

Group type: EXPERIMENTAL
Intervention: Early non-invasive ventilation (NIV)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Oxygen therapy alone
Number of subjects: 374
Study: 22438520

Group type: EXPERIMENTAL
Intervention: Vitamin E (600 IU every other day)
Number of subjects: 39815
Study: 20172371

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fine needle aspiration (FNA)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Traditional palpation-guided fine needle aspiration (FNA)
Number of subjects: 81
Study: 18622250

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 100 mg once daily
Number of subjects: 787

Group type: COMPARATOR
Intervention: Ibuprofen 600 mg three times daily
Number of subjects: 787
Study: 16208597

Group type: EXPERIMENTAL
Intervention: Valdecoxib (maximum single dose: 20 mg; cumulative dose: 35 mg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 41
Study: 11895538

Group type: COMPARATOR
Intervention: SRP (scaling and root planing)
Number of subjects: 111

Group type: COMPARATOR
Intervention: VEH (subgingival vehicle control)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: DOXI (subgingival application of 15% doxycycline gel)
Number of subjects: 111
Study: 9892589

Group type: EXPERIMENTAL
Intervention: C-Reactive Protein (CRP) levels
Number of subjects: 936
Study: 7548303

Group type: EXPERIMENTAL
Intervention: 2mg of VK1 orally
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (did not receive VK)
Number of subjects: 70
Study: 2183825

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 0
Study: 7323720

Group type: EXPERIMENTAL
Intervention: 1:3 jejunoileal ratio
Number of subjects: 34

Group type: COMPARATOR
Intervention: 3:1 jejunoileal ratio
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 34
Study: 31658543

Group type: EXPERIMENTAL
Intervention: rhGH treatment (0.2 IU·kg(‐1)·d(‐1) subcutaneously for 7 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: rhGH treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (anti-shock, anti-infection, and wound caring therapies)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 29388927

Group type: EXPERIMENTAL
Intervention: Supervised cycling training (SCT) for 3 months
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Home-based walking training (HBWT) for 3 months
Number of subjects: 114

Group type: COMPARATOR
Intervention: No exercise training (control group)
Number of subjects: 114
Study: 25428785

Group type: EXPERIMENTAL
Intervention: Xylitol gummy bears (7.8 g/day)
Number of subjects: 562

Group type: COMPARATOR
Intervention: Placebo gummy bears (inulin fiber 20 g/day)
Number of subjects: 562
Study: 24200027

Group type: EXPERIMENTAL
Intervention: Collagen conduit
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional microsurgical techniques (direct suture)
Number of subjects: 43
Study: 21295919

Group type: EXPERIMENTAL
Intervention: Alcohol Feedback
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control
Number of subjects: 119
Study: 19563189

Group type: EXPERIMENTAL
Intervention: Combination of Source Point and Back‐Shu Point group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine acupuncture group
Number of subjects: 80
Study: 18041353

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 15472191

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens 0.625 mg/d
Number of subjects: 489

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study: 11437895

Group type: EXPERIMENTAL
Intervention: Whiplash-injured subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 9564118

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (mean initial dose: 69.5 micrograms fentanyl/hr; mean final dose: 167.7 micrograms fentanyl/hr)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl
Number of subjects: 51
Study: 8091141

Group type: EXPERIMENTAL
Intervention: Misoprostol (600-800 micrograms/d)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Patients with an initial gastric ulcer
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Patients without an initial ulcer
Number of subjects: 83
Study: 3041972

Group type: EXPERIMENTAL
Intervention: 15 mg midazolam
Number of subjects: 61

Group type: COMPARATOR
Intervention: 15 mg oxazepam
Number of subjects: 61
Study: 29652246

Group type: EXPERIMENTAL
Intervention: Prolonged-release metformin (500 mg)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study: 26968357

Group type: EXPERIMENTAL
Intervention: Rigosertib 1800 mg per 24 h via 72-h continuous intravenous infusion administered every other week
Number of subjects: 299

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Rigosertib
Number of subjects: 299
Study: 23949961

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Younger males
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Males in connective tissue disease-associated PAH
Number of subjects: 1700
Study: 23358973

Group type: EXPERIMENTAL
Intervention: sirolimus
Number of subjects: 155

Group type: COMPARATOR
Intervention: non-sirolimus-based regimen
Number of subjects: 155
Study: 20022282

Group type: EXPERIMENTAL
Intervention: Estradiol antagonist (4 mg/day starting on the 25th day of the previous cycle)
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Estradiol antagonist
Number of subjects: 838

Group type: COMPARATOR
Intervention: Long agonist (Decapeptyl 0.1 mg starting on the 20th day of the previous cycle)
Number of subjects: 838
Study: 18506026

Group type: EXPERIMENTAL
Intervention: Postoperative cisplatin-based chemotherapy
Number of subjects: 4584

Group type: EXPERIMENTAL
Intervention: Postoperative cisplatin-based chemotherapy with vinorelbine
Number of subjects: 4584

Group type: EXPERIMENTAL
Intervention: Postoperative cisplatin-based chemotherapy with etoposide or vinca alkaloid
Number of subjects: 4584

Group type: EXPERIMENTAL
Intervention: Postoperative cisplatin-based chemotherapy with other drugs
Number of subjects: 4584
Study: 17068392

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg bid
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 12856812

Group type: EXPERIMENTAL
Intervention: Biological background knowledge
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Physiological theory of drug action curriculum
Number of subjects: 337
Study: 10699223

Group type: EXPERIMENTAL
Intervention: Short sleep duration
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: Insomnia symptoms
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: Subjective insufficient sleep
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: Sleep enhancing medication use
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: Young people
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: Overall sleep duration
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: Excessive daytime sleepiness
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: Insufficient sleep
Number of subjects: 3030
Study: 9337186

Group type: EXPERIMENTAL
Intervention: Phentolamine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8380243

Group type: EXPERIMENTAL
Intervention: Ganciclovir (6 mg/kg once per day after transplant)
Number of subjects: 85
Study: 2879752

Group type: EXPERIMENTAL
Intervention: lormetazepam (10 drops twice daily for 4 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: diazepam (10 drops twice daily for 4 weeks)
Number of subjects: 10
Study: 29569476

Group type: EXPERIMENTAL
Intervention: Unilateral lateral rectus resection under topical anesthesia
Number of subjects: 16
Study: 27206733

Group type: EXPERIMENTAL
Intervention: Educational intervention promoting healthy lifestyles, risk screening, and remote support (follow-up).
Number of subjects: 4170

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 4170

Group type: EXPERIMENTAL
Intervention: Intervention group (no specific intervention details provided).
Number of subjects: 4170

Group type: EXPERIMENTAL
Intervention: Passive dissemination strategy of providing training and materials.
Number of subjects: 4170
Study: 25409719

Group type: EXPERIMENTAL
Intervention: Back School program (group A)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Hydrotherapy program (group B)
Number of subjects: 56
Study: 22879423

Group type: EXPERIMENTAL
Intervention: 10 mg of lutein and 2 mg of zeaxanthin per day (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet alone (control group)
Number of subjects: 0
Study: 20451854

Group type: EXPERIMENTAL
Intervention: Medial rectus slanting recession (SLANT group)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Medial rectus recession with downward transposition (TRANS group)
Number of subjects: 18
Study: 18164454

Group type: EXPERIMENTAL
Intervention: Facet injections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiofrequency neurotomy
Number of subjects: 0
Study: 16403997

Group type: EXPERIMENTAL
Intervention: Unweighted group (Biodex Unweighing System at 25% body weight reduction)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Weighted group (weighted scuba-diving belt, increasing normal body weight by 5%)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Treadmill control group (treadmill training with no loading or unloading)
Number of subjects: 23
Study: 12745507

Group type: EXPERIMENTAL
Intervention: Nicotine patch with culturally sensitive self-help quitting materials
Number of subjects: 498

Group type: COMPARATOR
Intervention: Nicotine patch with standard self-help quitting materials
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 498
Study: 10365496

Group type: EXPERIMENTAL
Intervention: Behavioural Management (BM)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Intravenous Sedation (IVS)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Nitrous Oxide Sedation (NOS)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 211
Study: 8894914

Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted relaxation therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 1503282

Group type: EXPERIMENTAL
Intervention: Clonidine (4.9 +/- 0.3 micrograms.kg‐1)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Hydroxyzine alone (group T)
Number of subjects: 77
Study: 6391072

Group type: EXPERIMENTAL
Intervention: Oral propranolol combined with 2% pilocarpine
Number of subjects: 103

Group type: COMPARATOR
Intervention: 0.5% topical timolol combined with 2% pilocarpine
Number of subjects: 103
Study: 29233588

Group type: EXPERIMENTAL
Intervention: Moderate-carbohydrate and low glycemic index diet (LGI)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Moderate-carbohydrate and high glycemic index diet (HGI)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Low-fat and high glycemic index diet (LF)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Energy-restricted diets (general)
Number of subjects: 103
Study: 30344165

Group type: EXPERIMENTAL
Intervention: Paclitaxel and fluorouracil (TF) concurrent with radiotherapy
Number of subjects: 321

Group type: COMPARATOR
Intervention: Paclitaxel and cisplatin (TP) concurrent with radiotherapy
Number of subjects: 321

Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin (TC) concurrent with radiotherapy
Number of subjects: 321
Study: 27770771

Group type: EXPERIMENTAL
Intervention: Ambrisentan (5 mg once daily for 12 weeks, with dose titration to 10 mg allowed)
Number of subjects: 133
Study: 24246508

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (1 hour once a week for 10 weeks, aerobic exercises at 60-80% work capacity, resistance training, dyspnoea management)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (individual instruction in exercise training)
Number of subjects: 78
Study: 23158730

Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (omeprazole 0.8 - 1.0 mg/(kg·d) + amoxicillin-clavulanate 50 mg/(kg·d) for 5 days, followed by omeprazole 0.8 - 1.0 mg/(kg·d), clarithromycin 20 mg/(kg·d), and metronidazole 20 mg/(kg·d) for 5 days)
Number of subjects: 214

Group type: COMPARATOR
Intervention: 7-day triple therapy (omeprazole 0.8 - 1.0 mg/(kg·d), amoxicillin-clavulanate 50 mg/(kg·d), and clarithromycin 20 mg/(kg·d) for 7 days)
Number of subjects: 214

Group type: COMPARATOR
Intervention: 10-day triple therapy (omeprazole 0.8 - 1.0 mg/(kg·d), amoxicillin-clavulanate 50 mg/(kg·d), and clarithromycin 20 mg/(kg·d) for 10 days)
Number of subjects: 214

Group type: COMPARATOR
Intervention: 14-day triple therapy (omeprazole 0.8 - 1.0 mg/(kg·d), amoxicillin-clavulanate 50 mg/(kg·d), and clarithromycin 20 mg/(kg·d) for 14 days)
Number of subjects: 214
Study: 19843084

Group type: EXPERIMENTAL
Intervention: Triclosan-containing emollient
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 60
Study: 18496884

Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT) - 10 sessions of 2 hours, twice weekly
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cognitive Stimulation (CS) - 8 sessions of 1.5 hours, once weekly
Number of subjects: 25
Study: 15848712

Group type: EXPERIMENTAL
Intervention: Group 1 donor hearts (medically unsuitable)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Group 2 donor hearts (medically suitable)
Number of subjects: 144
Study: 12484580

Group type: EXPERIMENTAL
Intervention: Written information sheet
Number of subjects: 126

Group type: COMPARATOR
Intervention: Verbal information
Number of subjects: 126
Study: 9787945

Group type: EXPERIMENTAL
Intervention: Neoral formulation (1:1 dose-ratio conversion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neoral formulation (0.75 dose-ratio conversion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neoral formulation (1:1 and 0.75 dose-ratio conversion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Limited sampling strategy (three blood samples post-dosing of Neoral formulation)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neoral formulation
Number of subjects: 30
Study: 7707126

Group type: COMPARATOR
Intervention: Interferon alfa‐2a (3 x 10(6) U subcutaneously three times per week)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Pentostatin (4 mg/m2 intravenously every 2 weeks)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Pentostatin
Number of subjects: 313
Study: 2697951

Group type: EXPERIMENTAL
Intervention: Dimethyl sulfoxide (DMSO)
Number of subjects: 42
Study: 46951

Group type: EXPERIMENTAL
Intervention: Nicotinic-acid analogue (N.A.A.) given within 12 hours of myocardial infarction onset
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Nicotinic-acid analogue (N.A.A.)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 31924718

Group type: EXPERIMENTAL
Intervention: Projection Space Synthesis (PSS)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Image Space Synthesis (PIS)
Number of subjects: 140
Study: 30519704

Group type: EXPERIMENTAL
Intervention: Slip-resistant footwear (SRF) program
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group (no SRF program)
Number of subjects: 226
Study: 27650383

Group type: EXPERIMENTAL
Intervention: Two primary endpoints in the Social Fitness study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of superiority and non-inferiority aims for the endpoints
Number of subjects: 0
Study: 25874122

Group type: EXPERIMENTAL
Intervention: Inhibitory control (Go‐Nogo paradigm)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Cognitive flexibility task
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Sustained attention task
Number of subjects: 498
Study: 23328339

Group type: EXPERIMENTAL
Intervention: Psychoeducational treatment (9 sessions of 2 hours each: 5 sessions of education about the illness + 4 sessions of autogenic relaxation)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Psychoeducational treatment
Number of subjects: 216
Study: 20683595

Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg every 3 weeks for six cycles
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg every 3 weeks for six cycles
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pamidronate (both dosages)
Number of subjects: 70
Study: 19244366

Group type: EXPERIMENTAL
Intervention: Oily fish (average of one serving every 5 days)
Number of subjects: 1119

Group type: EXPERIMENTAL
Intervention: Wine (average of half a glass a day)
Number of subjects: 1119

Group type: COMPARATOR
Intervention: Dietary patterns
Number of subjects: 1119